INR-Triggered Transfusion In GI Bleeders From ER

Stopped early · Phase 3

Conditions studied: Respiratory Distress Syndrome, Adult, Gastrointestinal Hemorrhage, Liver Diseases, Transfusion Related Lung Injury

In brief

Transfusion-related acute lung injury (TRALI) is the most common cause of transfusion-related morbidity and mortality in the United States. It is very common and often unrecognized in the critically ill with the greatest incidence occurring in bleeding patients with liver disease. Plasma is the most blood component associated with this deadly complication and therefore patients with liver disease who frequently receive transfused plasma are at increased risk. The optimal plasma transfusion strategy for bleeding patients with liver disease is unknown and the investigators will evaluate this clinical question in a small pilot randomized controlled trial. The invstigators hypothesize that targetting a more restrictive INR Target (2.5) vs. an INR Target (1.8) will result in less hypoxemia, a TRALI surrogate without increasing bleeding complications.

Key facts

Study ID
NCT01461889
Run by
University of Colorado, Denver
People needed
50
Starts
2011-07-01
Expected to finish
2015-08-01
Last updated by the study team
2017-03-27

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.